COHBAR INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch COHBAR INC and buy or sell other stocks, ETFs, and their options commission-free!

About CWBR

CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA. 

CEO
Joseph J. Sarret, MD
CEOJoseph J. Sarret, MD
Employees
—
Employees—
Headquarters
Menlo Park, California
HeadquartersMenlo Park, California
Founded
2007
Founded2007
Employees
—
Employees—

CWBR Key Statistics

Market cap
1.19M
Market cap1.19M
Price-Earnings ratio
—
Price-Earnings ratio—
Dividend yield
—
Dividend yield—
Average volume
—
Average volume—
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$1.01
52 Week high$1.01
52 Week low
—
52 Week low—

Stock Snapshot

The current COHBAR INC(CWBR) stock price is $0.41, with a market capitalization of 1.19M.

During the trading day, COHBAR INC(CWBR) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for COHBAR INC(CWBR) stock has reached 0.

People also own

Based on the portfolios of people who own CWBR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.